Keywords: Pierre Fabre, Joncia, Milnaciprin, Fibromyalgia, Australia, TGA, Dextropropoxyphene, Aspen Pharma
Pierre Fabre gains approval for fibromyalgia drug Joncia in Australia; TGA cancels approval for four painkillers
Article | 22 November 2011
Independent French drugmaker Pierre Fabre says that the Australian regulator the Therapeutic Goods Administration (TGA) has granted market authorization milnacipran ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
